



British Pharmacopoeia

British Pharmacopoeia Commission Secretariat

MHRA, 10 South Colonnade
Canary Wharf, London, E14 4PU
United Kingdom

www.pharmacopoeia.com

Date: 15 October 2018

TO WHOM IT MAY CONCERN

ENOXAPARIN SODIUM INJECTION BP 2019

RELATED SUBSTANCES

It has come to our attention that the limits in the Related substances test for Enoxaparin Sodium Injection in the BP 2019 contain an error.

The limits will be amended as follows, the changed text has been highlighted:

LIMITS

In the chromatogram obtained with solution (2):
the area of the peak due to dermatan sulfate and chondroitin sulfate is not greater than **half** the area of the corresponding peak in the chromatogram obtained with solution (6) (2.0%);
no peaks other than the peak due to dermatan sulfate and chondroitin sulfate are detected.

Please accept this as a notice of intent to amend the monograph on behalf of the British Pharmacopoeia Commission. This letter is for information only and does not represent a legally-enforceable standard. The revised monograph will be published in a future edition of the British Pharmacopoeia - the current target publication is the BP 2020.

If you have any questions concerning this letter, please do not hesitate to contact the British Pharmacopoeia Secretariat at the address above.

Yours faithfully,

MR JAMES POUND

Secretary & Scientific Director

E-mail: BPCOM@mhra.gov.uk